[Question] how do you actually verify half-life
how do you actually verify half-life. I am not trying to be the "source?" guy. I would just like a source.
Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.
Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.
GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.
a mechanism you can state is not a mechanism you have demonstrated
albumin binding is most of the half-life story
the peripheral and central stories are not in competition
the peripheral and central stories are not in competition
Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.
glucagon agonism sounds paradoxical until you read the energy expenditure work
Tried to build a mental model from mechanism alone and produced a confident prediction that the trial data flatly contradicted.
What was the exposure in that experiment relative to therapeutic?
Left up and flaired Explainer. This is the standard of post the board was created for.
The mental model, in four steps, that makes the rest of this site legible.
One: gut hormones amplify the insulin response to food. Two: agonists at those receptors act peripherally on insulin secretion and gastric emptying, and centrally on appetite. Three: structural modification gives them a long half-life, so exposure is smooth and weekly. Four: tolerance develops to some effects and not to others.
From those four, most of what the experience boards report falls out: why the side effects cluster early, why they settle at a stable dose, why appetite reduction persists, and why the scale and the appetite move on different clocks.
Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.
Agreed — the incretin effect is the load-bearing concept and everything downstream reads differently once you have it.
- 1Long half-life in this class comes from structural modification that…6 comments in this branch · started by u/emil_agyeman